Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study.

@article{Huang2016IcotinibIP,
  title={Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study.},
  author={Jing Huang and Qingxia Fan and Ping Jung Lu and Jianming Ying and Changwu Ma and Wei Liu and Ying Liu and Fenlai Tan and Yan Sun},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2016},
  volume={11 6},
  pages={910-7}
}
INTRODUCTION Epidermal growth factor receptor (EGFR) has been reported to be overexpressed and amplified in a high percentage of patients with esophageal squamous cell carcinoma (ESCC). The activity of icotinib, an EGFR tyrosine kinase inhibitor, was assessed in previously treated ESCC with EGFR overexpression or amplification. METHODS For this phase 2, single-arm, multicenter trial undertaken at six hospitals in China, we included Chinese patients with previously treated, histologically… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…